A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder

[摘要] Objective: Major depressive disorder is often chronic, with relapse and recurrence common. Levomilnacipran extended-release is a potent and selective serotonin and reuptake inhibitor approved in the United States for treatment of major depressive disorder in adults. The objective of this study ({"type":"clinical-trial","attrs":{"text":"NCT01085812","term_id":"NCT01085812"}}NCT01085812) was to evaluate the efficacy, safety, and tolerability of levomilnacipran extended-release in the prevention of relapse in patients with major depressive disorder.

[学科分类] 精神健康和精神病学

[关键词] Levomilnacipran;antidepressants;serotonin and norepinephrine reuptake inhibitor (SNRI);major depressive disorder;major depressive disorder relapse